Relevant bibliographies by topics / Biologics

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Biologics'

Author: Grafiati
Published: 4 June 2021
Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Biologics.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Biologics"

1

Agrahari, Aman, Vipin Kesharwani, Shashi Singh, and Nandini Nath. "Bridging the Gap: Investigating the State-of-the-Art Approaches in Oral Biologic Delivery and Their Role in Redefining Therapeutic Possibilities." International Journal of Medical Sciences and Pharma Research 10, no. 4 (2024): 1–8. https://doi.org/10.22270/ijmspr.v10i4.100.

Full text
Abstract:
Biopharmaceutical medications that originate from biological sources and processes are known as biologics. Biologics are now the most promising medications for oral use in treating a variety of illnesses. These illnesses may involve problems with inflammation and metabolism. It has been established that the most practical way to provide medication is by oral delivery of biologics. Due to the simplicity of taking doses, patients are observed to be directed towards the oral drug, demonstrating its great effectiveness. Even though biologicals are the most promising medicine, oral delivery of thes
APA, Harvard, Vancouver, ISO, and other styles
2

Vuckovic, C., A. Cremer, C. Minsart, et al. "P0367 A Clustering approach to discriminate slow and rapid biologics switchers in difficult-to-treat Crohn’s Disease patients." Journal of Crohn's and Colitis 19, Supplement_1 (2025): i842—i844. https://doi.org/10.1093/ecco-jcc/jjae190.0541.

Full text
Abstract:
Abstract Background CD patients exhibit highly variable responses to biologics. While some patients achieve sustained remission with only one biologic over the course of their disease, other will require the sequencing of multiple biologics (“difficult-to-treat” patients) for optimal disease control. The aim of this study was to delineate the profile of treatment regimen of the biological exposed CD patients with luminal disease. Methods Among CD patients diagnosed between 1999 and 2019 with B1 phenotype at diagnosis, 203 patients who maintained this phenotype at maximum follow-up (FU, median
APA, Harvard, Vancouver, ISO, and other styles
3

Adami, Giovanni, Kenneth G. Saag, Roland D. Chapurlat, et al. "Balancing benefits and risks in the era of biologics." Therapeutic Advances in Musculoskeletal Disease 11 (January 2019): 1759720X1988397. http://dx.doi.org/10.1177/1759720x19883973.

Full text
Abstract:
Biologics are substances synthetized from biological sources used in the prevention and treatment of several diseases. Rheumatologists have many years of experience with biologics for the treatment of immune-mediated diseases and osteoporosis. Randomized clinical trials and postmarketing studies have demonstrated that treatment with biologics can result, albeit infrequently, in serious adverse events. To date, several risk mitigation strategies have been identified and implemented. The objective of the present perspective review is to examine the risk mitigation strategies of biologic treatmen
APA, Harvard, Vancouver, ISO, and other styles
4

Farih, S., H. Rkain, S. Fellous, et al. "POS1417 DO SOCIAL FACTORS IMPACT ON BIOLOGICS COSTS IN RHEUMATOID ARTHRITIS? RESULTS FROM THE MOROCCAN RBSMR REGISTRY." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 992.2–992. http://dx.doi.org/10.1136/annrheumdis-2021-eular.4225.

Full text
Abstract:
Background:Objectives:The aim of this study was to estimate the annual direct cost of biologics in rheumatoid arthritis and to evaluate the impact of social factors on biological use and costs.Methods:Patients in the Moroccan register of biologicals (RBSMR) with available 1-year data were included. Variables related to socio-economic status, disease and biological were collected. Direct costs included prices of biologics, costs of infusions, and subcutaneous injections. Biological use and costs were compared based on social factors.Results:Our study included 197 patients (female sex of 86.8%,
APA, Harvard, Vancouver, ISO, and other styles
5

Jagruti, Pansare* Shraddha Bhalake Sayali Erande Ragini Patil. "Biosimilar Drug: Current Situation." International Journal of Pharmaceutical Sciences 2, no. 11 (2024): 1674–79. https://doi.org/10.5281/zenodo.14246072.

Full text
Abstract:
Biopharmaceuticals, derived from living cells through biological processes, replicate natural substances like hormones, offering targeted treatments for various diseases. As patents for original biologic drugs expire, biosimilars—subsequent versions of these drugs with similar but not identical characteristics—have emerged as cost-effective alternatives. In India, these are termed "similar biologics," with regulatory guidelines ensuring their safety, efficacy, and quality. Biosimilars are categorized based on their production processes, regulatory pathways, and branding strategies.
APA, Harvard, Vancouver, ISO, and other styles
6

Vadstrup, K., S. Alulis, A. Borsi, et al. "DOP78 Intestinal surgery rates in ulcerative colitis and Crohn’s disease in the era of biologics: A Danish Nationwide Register Study from 2003 to 2016." Journal of Crohn's and Colitis 14, Supplement_1 (2020): S116—S117. http://dx.doi.org/10.1093/ecco-jcc/jjz203.117.

Full text
Abstract:
Abstract Background Biologic response modifiers (biologics) has been introduced as potent drugs for the treatment of Crohn’s disease (CD) and ulcerative colitis (UC). Whether this has resulted in a reduction in the need for surgical treatment is controversial. This study aims to explore the surgery rates of patients diagnosed with CD and UC between 2003 and 2015 and correlate to those treated with biologics or not in Denmark with a follow-up until 2016. Methods This national register study included patients diagnosed between 2003 and 2015 and followed up until 2016, identified in the Danish Na
APA, Harvard, Vancouver, ISO, and other styles
7

Lin, R. J. "The Biological Response to Biologics." Science Translational Medicine 3, no. 80 (2011): 80ec61. http://dx.doi.org/10.1126/scitranslmed.3002541.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

S, Patil Prasad. "Biosimilars: The Future of Biologic Therapy." International Journal for Research in Applied Science and Engineering Technology 13, no. 4 (2025): 1449–65. https://doi.org/10.22214/ijraset.2025.68559.

Full text
Abstract:
Chronic diseases are continuing to rise globally, emphasizing the need for patients to have access to safe and effective treatments. Biologics represent a unique and powerful class of medications that have significantly changed how doctors manage conditions like cancer, diabetes, and autoimmune diseases. These treatments have led to outstanding patient outcomes—for example, biologics have halved the mortality rate for non-Hodgkin’s lymphoma. Presently, there are over 200 biologics and vaccines available worldwide, most of which are therapeutic proteins—lab-engineered proteins used in medicine,
APA, Harvard, Vancouver, ISO, and other styles
9

Furer, Victoria, and Ori Elkayam. "Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis." Rambam Maimonides Medical Journal 14, no. 2 (2023): e0007. http://dx.doi.org/10.5041/rmmj.10494.

Full text
Abstract:
Treatment with biological agents has become standard of care in treatment of immune-mediated diseases (IMD), including rheumatoid arthritis and psoriatic arthritis. Yet, a significant proportion of patients experience loss of response to biologics, need treatment escalation, or develop side effects. During the past decade, new biologic agents with different targeted molecular pathways have been approved for treatment of IMD, introducing the possibility of concomitant dual biologic therapy. The role of dual biologic therapy targeting different inflammatory pathways has become an area of great i
APA, Harvard, Vancouver, ISO, and other styles
10

Vender MD FRCPC, Ronald. "Transitioning Between Biologics." SKIN The Journal of Cutaneous Medicine 3, no. 6 (2019): 374–80. http://dx.doi.org/10.25251/skin.3.6.2.

Full text
Abstract:
Background: Transitioning between biologics has become an important part of practice.Objective: Patients with moderate to severe plaque psoriasis who are on biologics can have efficacy failures, as well as safety concerns. This would often necessitate a change of biologic, which may be within the same class or to a different class. A change due to an adverse event from the presently used biologic may resolve or require treatment until a new biologic is introduced, which may pose some delay in the initiation of the subsequent biologic. Methods: A review of the literature and guidelines publishe
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Biologics"

1

Conant, Tamara L. (Tamara Lynn). "Modeling variability for biologics strategic planning." Thesis, Massachusetts Institute of Technology, 2009. http://hdl.handle.net/1721.1/53311.

Full text
Abstract:
Thesis (S.M.)--Massachusetts Institute of Technology, Dept. of Electrical Engineering and Computer Science; and, (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management; in conjunction with the Leaders for Manufacturing Program at MIT, 2009.<br>Cataloged from PDF version of thesis.<br>Includes bibliographical references (p. 46).<br>Making strategic decisions about resource capabilities in the uncertain business of drug development is a challenging task. Novartis, a Swiss pharmaceutical company, is expanding from its success in small molecule therapeutics into the attractive
APA, Harvard, Vancouver, ISO, and other styles
2

Pasanek, David M. "The conclusion of a biologic's lifecycle : manufacturing sourcing strategies on the eve of follow-on biologics." Thesis, Massachusetts Institute of Technology, 2008. http://hdl.handle.net/1721.1/44321.

Full text
Abstract:
Thesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management; and, (S.M.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering; in conjunction with the Leaders for Manufacturing Program at MIT, 2008.<br>Includes bibliographical references (p. [80]-87).<br>The Amgen Rhode Island facility is dedicated to the production of the biological bulk drug substance (BDS) for Enbrel® (etanercept), which blocks the action of one's immune system, helping to treat immune diseases, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.
APA, Harvard, Vancouver, ISO, and other styles
3

Shama, Leslie Marie. "Risk Assessment of Plant-Based Pharmaceuticals and Biologics." Thesis, Montana State University, 2006. http://etd.lib.montana.edu/etd/2006/shama/ShamaL1206.pdf.

Full text
Abstract:
Biotechnology is evolving to produce pharmaceutical proteins in plants. Plantbased pharmaceutical production creates concerns of exposure in an open environment and contamination of the food supply. Consequently, quantitative human health and ecological risk assessments were conducted for aprotinin, gastric lipase, and LT-B expressed in maize. A comparative, qualitative risk assessment was conducted for conventionally derived and plant-cell derived Newcastle disease virus vaccine. Effect and exposure scenarios were modeled for each quantitative risk assessment and each scenario was based on a
APA, Harvard, Vancouver, ISO, and other styles
4

Luo, Sifo. "Capacity planning under demand and manufacturing uncertainty for biologics." Thesis, Massachusetts Institute of Technology, 2017. http://hdl.handle.net/1721.1/112865.

Full text
Abstract:
Thesis: M. Eng. in Supply Chain Management, Massachusetts Institute of Technology, Supply Chain Management Program, 2017.<br>Cataloged from PDF version of thesis.<br>Includes bibliographical references (page 58).<br>Due to the long lead times and complexity in drug development and approval processes, pharmaceutical companies use long range planning to plan their production for the next 10 years. Capacity planning is largely driven by the long-term demand and its forecast uncertainty. The impact of uncertainties at manufacturing level, such as factory productivity and production success rate, a
APA, Harvard, Vancouver, ISO, and other styles
5

Jain, Saurabh Ashok. "The development of biologics for use in translational medicine." Thesis, University of Edinburgh, 2015. http://hdl.handle.net/1842/21117.

Full text
Abstract:
In this research, we developed a wide range of biological tools against two distinct targets from future diagnostic or therapeutic points of view. Firstly, we demonstrate that sporadic canine B cell lymphoma mimics the features of human equivalents which in turn will be advantageous for development of canine as well as human therapeutics. With a comparative oncological approach, here we developed a monoclonal antibody (NCD1.2) against canine CD20 which also binds to its human counterpart. Using flow cytometry and tissue microarray, we show that NCD1.2 binds specifically to canine B cell lympho
APA, Harvard, Vancouver, ISO, and other styles
6

Cox, Felicia C. A. I. "Experimental methodology for non-thermal effects of electromagnetic radiation on biologics." Thesis, Massachusetts Institute of Technology, 2006. http://hdl.handle.net/1721.1/36778.

Full text
Abstract:
Thesis (M. Eng.)--Massachusetts Institute of Technology, Dept. of Electrical Engineering and Computer Science, 2006.<br>Includes bibliographical references (p. 133-137).<br>Appropriate equipment is needed for research on the effects of radio-frequency radiation from radio-frequency identification (RF-ID) systems on biological materials. In the present study, a complete test system comprising assembled hardware and custom-built software was developed for a research project investigating whether RFID radiation produces significant effects in biologics. Furthermore, we document a method for deter
APA, Harvard, Vancouver, ISO, and other styles
7

Chun, Soo Jin S. M. Massachusetts Institute of Technology. "Brokering strategic partnerships between Asian and western biopharmaceutical companies in the global biologics market : assessment of capabilities of Asian participants in the biologics contract manufacturing organization marketplace." Thesis, Massachusetts Institute of Technology, 2009. http://hdl.handle.net/1721.1/63014.

Full text
Abstract:
Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology, 2009.<br>Cataloged from PDF version of thesis.<br>Includes bibliographical references (p. 51-58).<br>It has become increasingly important for companies in the biopharmaceutical industry to maximize the clinical, commercial and economic impact of their products on a global scale. In this context, both Western and Asian firms have been engaging in international merger and acquisition (M&A) activities to improve global capabilities and competiveness. The M&A activities in the sector are driven by near-term expiration of blockb
APA, Harvard, Vancouver, ISO, and other styles
8

Rorrer, Rebecca Kathleen. "Veterinary Therapeutic and Biologic Agents in Virginia Sheep Production." Thesis, Virginia Tech, 2002. http://hdl.handle.net/10919/34574.

Full text
Abstract:
Biological and therapeutic agents are used in food animal production to maintain animal health and well being, prevent and treat disease, and to maintain or enhance production. Concerns about the use of pharmaceutical agents in food animal production have been raised, especially in relation to food quality and safety. This study addressed the scarcity of information concerning the quantity of pharmaceuticals being used and the reasons for their use in sheep production. Additional goals included determining the sources of information used by shepherds in making treatment decisions and evalua
APA, Harvard, Vancouver, ISO, and other styles
9

Atzinger, Christopher B. "Impact of Ultrasonography on use of Biologics in Patients with Rheumatoid Arthritis." University of Cincinnati / OhioLINK, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1522165400676313.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Volk, Anna-Luisa. "Cell line and protein engineering tools for production and characterization of biologics." Doctoral thesis, KTH, Proteomik och nanobioteknologi, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-212931.

Full text
Abstract:
Our increasing understanding of disease mechanisms coupled with technological advances has facilitated the generation of pharmaceutical proteins, which are able to address yet unmet medical needs. Diseases that were fatal in the past can now be treated with novel biological medications improving and prolonging life for many patients. Pharmaceutical protein production is, however, a complex undertaking, which is by no means problem-free. The demand for more complex proteins and the realization of the importance of post-translational modifications have led to an increasing use of mammalian cells
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Biologics"

1

Feng, Xiaodong, Hong-Guang Xie, Ashim Malhotra, and Catherine F. Yang. Biologics and Biosimilars. CRC Press, 2022. http://dx.doi.org/10.1201/9780429485626.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Boehncke, Wolf-Henning, and Heinfried H. Radeke, eds. Biologics in General Medicine. Springer Berlin Heidelberg, 2007. http://dx.doi.org/10.1007/978-3-540-29018-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Varshney, Dushyant, and Manmohan Singh, eds. Lyophilized Biologics and Vaccines. Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2383-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Baldo, Brian A. Safety of Biologics Therapy. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-30472-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Directorate, Canada Drugs. Inspection of biologics manufacturers. Health and Welfare Canada = Santé et bien-être social Canada, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

AGRICULTURE, US DEPARTMENT OF. Veterinary biologics: use and regulation. U.S. Dept. of Agriculture, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

P, Mathieu Mark, ed. Biologics development: A regulatory overview. PAREXEL International Corp., 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Crandall, Mary Anne. The market for generic biologics. Edited by Heffner Steven and Kalorama Information LLC. Kalorama Information, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

United States. Animal and Plant Health Inspection Service. Veterinary biologics: Use and regulation. 2nd ed. U.S. Dept. of Agriculture, Animal and Plant Health Inspection Service, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

United States. Animal and Plant Health Inspection Service, ed. Veterinary biologics: Use and regulation. U.S. Dept. of Agriculture, Animal and Plant Health Inspection Service, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Biologics"

1

Mitropoulos, Panoglotis, and Robert A. Norman. "Biologics." In Preventive Dermatology in Infectious Diseases. Springer London, 2011. http://dx.doi.org/10.1007/978-0-85729-847-8_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sekhon, Sahil, Caleb Jeon, and Wilson Liao. "Biologics." In Updates in Clinical Dermatology. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-90107-7_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Prinz, Jörg C. "Biologics." In Fortschritte der praktischen Dermatologie und Venerologie. Springer Berlin Heidelberg, 2005. http://dx.doi.org/10.1007/3-540-28691-8_34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jilma, Bernd, and Markus Müller. "Biologics." In Clinical Pharmacology: Current Topics and Case Studies. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-27347-1_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mitropoulos, Panoglotis, and Robert A. Norman. "Biologics." In Preventive Dermatology. Springer London, 2010. http://dx.doi.org/10.1007/978-1-84996-021-2_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Baldo, Brian A., and Nghia H. Pham. "Biologics." In Drug Allergy. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-7261-2_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Yalamanchili, Praveen K., and Scott D. Boden. "Fusion Biologics." In Minimally Invasive Spine Surgery. Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4614-5674-2_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chang, Byeong S., Michael Reilly, and Hana Chang. "Lyophilized Biologics." In Lyophilized Biologics and Vaccines. Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2383-0_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Eaglstein, William H. "What Are Biologics, Biological Products and Biological Drugs?" In The FDA for Doctors. Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-08362-9_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Scott, Ian C., James B. Galloway, and David L. Scott. "Biologics – An Overview." In Inflammatory Arthritis in Clinical Practice. Springer London, 2015. http://dx.doi.org/10.1007/978-1-4471-6648-1_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Biologics"

1

Pope, Tia, and Ahmad Patooghy. "BioChk: A Regulation-Aligned Quality Assurance Framework for AI-Generated Biologics." In 2025 IEEE Conference on Artificial Intelligence (CAI). IEEE, 2025. https://doi.org/10.1109/cai64502.2025.00253.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Tsegaye, Anteneh A., Daniel P. Furr, Gunnar Olson, and Susan R. Trammell. "Light-Assisted Drying (LAD) for the Stabilization of Biologics at Ambient Temperature." In CLEO: Applications and Technology. Optica Publishing Group, 2024. http://dx.doi.org/10.1364/cleo_at.2024.jtu2a.180.

Full text
Abstract:
Light-assisted drying (LAD) is a new technique that uses near-infrared (1064 nm) laser light to selectively heat water, quickly dehydrating samples and forming an amorphous trehalose preservation matrix that can be stored at supra-zero temperatures.
APA, Harvard, Vancouver, ISO, and other styles
3

Arts, Chris. "Biologics in Spine." In eccElearning Postgraduate Diploma in Spine Surgery. eccElearning, 2017. http://dx.doi.org/10.28962/01.3.010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bonné, R., R. T. Eachembadi, K. Wouters, and J. V. Manca. "Biological Nanofibers with Record Intrinsic Electrical Properties – towards e-Biologics." In 2023 IEEE Nanotechnology Materials and Devices Conference (NMDC). IEEE, 2023. http://dx.doi.org/10.1109/nmdc57951.2023.10344143.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Isenberg, David. "26 Combinations of biologics." In 13th Annual Meeting of the Lupus Academy, Hybrid Annual Meeting (Amsterdam), September 6–8, 2024. Lupus Foundation of America, 2024. http://dx.doi.org/10.1136/lupus-2024-la.27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Voskuyl, Alexandre. "21 Managing biologics in lupus." In 13th Annual Meeting of the Lupus Academy, Hybrid Annual Meeting (Amsterdam), September 6–8, 2024. Lupus Foundation of America, 2024. http://dx.doi.org/10.1136/lupus-2024-la.21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Dall’Era, Maria. "20 Managing biologics in lupus." In 13th Annual Meeting of the Lupus Academy, Hybrid Annual Meeting (Amsterdam), September 6–8, 2024. Lupus Foundation of America, 2024. http://dx.doi.org/10.1136/lupus-2024-la.20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kubasova, E., and N. Shuliko. "THE ACTIVITY OF MICROORGANISMS IN THE RHIZOSPHERE OF GRAIN CROPS UNDER THE APPLICATION OF SEED BACTERIZATION." In «PROBLEMS OF SOIL FERTILITY IN MODERN AGRICULTURE». Krasnoyarsk Scientific Research Institute of Agriculture is a separate division of the Federal Research Center KSC SB RAS, 2024. http://dx.doi.org/10.52686/9785605087878_307.

Full text
Abstract:
In the field experiment, the analysis of the effect of biologics "Mizorin" and "Flavobacterin" on the number of microorganisms of the oligonitrophil group in the dynamics of vegetation of grain crops was carried out, and the dependence of crop yields on the activity of soil microorganisms was estimated. The study was carried out in 2023 in the fields of the Omsk ASC. The positive effect of the use of biological preparations on biological activity has been established, in particular, an increase in the number of microorganisms of the oligonitrophil group up to 55% in the rhizosphere of durum wh
APA, Harvard, Vancouver, ISO, and other styles
9

Cardell, Lars-Olaf, and Constance de Koning. "The role of biologics in CRSwNP." In Nordic Lung Congress 2022, edited by Lars-Olaf Cardell and Vibeke Backer. Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/cb283d91.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Caminati, Marco, Gabriella Guarnieri, Diego Bagnasco, et al. "BIOLOGICS SWITCH IN SEVERE EOSINOPHILIC ASTHMA." In ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa879.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Biologics"

1

Sitney, Karen, Rashmi Rawat, Beatrix Metzner, et al. Cumulative Stability for Biologics. BioPhorum, 2024. http://dx.doi.org/10.46220/2024regx002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Jaumann, Florian, Jan Schoening, Oscar Lara-Velasco, et al. Trends in outsourcing of CMC development services for biologics. BioPhorum, 2021. http://dx.doi.org/10.46220/2021dg002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tadrpis, Mina, Daniel McCormack, Diana Martins, Sophie Kitchen, Samana Singh, and Tara Gomes. Current and prospective utilization of innovator biologics and biosimilars in Ontario. ODPRN, 2020. http://dx.doi.org/10.31027/odprn.2020.01.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Trusheim, Mark, Murray Aitken, and Ernst Berndt. Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules? National Bureau of Economic Research, 2010. http://dx.doi.org/10.3386/w16014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Huang, Chih-Wen, Hsu-Heng Yen, and Yang-Yuan Chen. Pregnancy Safety of Biologics in IBD: A Systematic Review and Network Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2025. https://doi.org/10.37766/inplasy2025.4.0012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lucas, Paul, John McKnight, Agata Chodynska Piatkowska, et al. An industry reflection on the application of the Russian Pharmacopeia to the registration of biologics. BioPhorum, 2021. http://dx.doi.org/10.46220/2021reg003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

lee, haur yueh, and karen Choo. Risk of Eczema Herpeticum in atopic dermatitis patients receiving JAK inhibitors, biologics or other systemic therapy. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.10.0069.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Weng, Chenghua, Leixi Xue, Qing Lu, Jiajun Xu, Zhichun Liu, and Wentian Wang. Comparative efficacy and safety of Janus kinase inhibitors and biologics in rheumatoid arthritis: a systematic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.3.0017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lai, Chien-Cheng, Shih-Chieh Shao, Ethan Tsai, and Ching-Chi Chi. Efficacy and safety of biologics and small molecules inhibitors in treating genital psoriasis: A systematic review of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2024. http://dx.doi.org/10.37766/inplasy2024.4.0117.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Li, Yuelu, Xianming Fan, Dan Luo, Huan Zong, Zhangyong Song, and Wenbi Chen. Efficacy of Different Biologics in the Treatment of Moderate-to-Severe Allergic Asthma: A Systematic Review and Network Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2025. https://doi.org/10.37766/inplasy2025.3.0129.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Biologics' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography